Online citations, reference lists, and bibliographies.
← Back to Search

Economic Costs Of Overactive Bladder In The United States.

M. Ganz, Amy Smalarz, T. Krupski, J. Anger, J. Hu, K. Wittrup-Jensen, C. Pashos
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
OBJECTIVES To calculate, from a societal perspective, current direct (medical and nonmedical) and indirect costs of overactive bladder (OAB) in the United States and project them to future years. Existing cost assessments of OAB in the United States are incomplete and outdated. METHODS A prevalence-based model was developed incorporating age- and sex-specific OAB prevalence rates, usage data, and productivity data. On the basis of the information gathered from the recent 5 years of the medical literature, practice guidelines, Medicare and managed care fee schedules, and expert panel input, the annual per capita and total US costs were calculated for 2007. US census population forecasts were used to project the costs of OAB to 2015 and 2020. RESULTS In 2007, average annual per capita costs of OAB were $1925 ($1433 in direct medical, $66 in direct nonmedical, and $426 in indirect costs). Applying these costs to the 34 million people in the United States with OAB results in total national costs of $65.9 billion (billion = 1000 million), ($49.1 billion direct medical, $2.3 billion direct nonmedical, and $14.6 billion indirect). Average annual per capita costs in 2015 and 2020 would be $1944 and $1969 and total national costs would be $76.2 billion and $82.6 billion, respectively. CONCLUSIONS These data suggest that the economic burden of OAB is about 5-fold higher than older, noncomprehensive estimates. These costs are higher than previously published data for the United States and Europe because this analysis relies on more current data, real world age- and sex-specific treatment patterns and costs, and includes a more complete set of cost components.
This paper references
10.1111/j.1464-410X.2008.07601.x
The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well‐being in men and women: results from the EPIC study
K. Coyne (2008)
10.1097/01.jom.0000161744.21780.c1
Employees With Overactive Bladder: Work Loss Burden
E. Wu (2005)
10.1016/J.EURURO.2006.04.018
The current and future burden and cost of overactive bladder in five European countries.
P. Reeves (2006)
The economic costs of illness: A replication and update
D. Rice (1985)
10.1016/J.UROLOGY.2003.10.037
Costs of urinary incontinence and overactive bladder in the United States: a comparative study.
T. Hu (2004)
10.1016/S0022-5347(05)00313-7
Overactive bladder: a better understanding of pathophysiology, diagnosis and management.
A. Wein (2006)
10.1111/j.1464-410X.2005.05654.x
Health‐related consequences of overactive bladder: an economic perspective
T. Hu (2005)
10.1002/0471667196.ess2527
Statistical abstract of the United States
D. Commerce (1878)
Overactive bladder: special considerations in the geriatric population.
J. Ouslander (2000)
10.1007/s00345-002-0301-4
Prevalence and burden of overactive bladder in the United States
W. Stewart (2002)
10.1016/S0090-4295(02)02243-4
The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.
P. Abrams (2002)
10.1002/NAU.10052
The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence Society
P. Abrams (2002)
10.1016/J.EURURO.2006.11.040
The economic costs of overactive bladder in Germany.
T. Klotz (2007)
10.1592/phco.26.12.1694
Pharmacoeconomic Evaluation of Antimuscarinic Agents for the Treatment of Overactive Bladder
Y. Ko (2006)
10.1097/01.AOG.0000206213.48334.09
The “Costs” of Urinary Incontinence for Women
L. Subak (2006)
10.1016/S0140-6736(06)67925-7
Urinary incontinence in women
P. Norton (2006)



This paper is referenced by
10.1007/s00192-020-04325-1
Percutaneous tibial nerve stimulation maintenance therapy for overactive bladder in women: long-term success rates and adherence
Carrie E. Jung (2020)
10.1007/s11934-017-0662-2
Management of Overactive Bladder in the Face of High Grade Prolapse
Juan M. Guzman-Negron (2017)
10.1007/s00192-012-2000-z
The effect of pelvic organ prolapse severity on improvement in overactive bladder symptoms after pelvic reconstructive surgery
J. M. Miranne (2012)
10.1152/ajprenal.00021.2015
New impetus for innovation in benign urology.
Warren G Hill (2015)
10.26481/dis.20180305mw
Multi-methodological approaches to investigate lower urinary tract function in health and disease
M. Walter (2018)
10.2165/11539020-000000000-00000
Vulnerable Elderly Patients and Overactive Bladder Syndrome
S. Kraus (2010)
10.1007/s11884-018-0496-x
Salvage Combination Therapies for Refractory Overactive Bladder
S. Martin (2018)
10.1007/s00192-014-2417-7
Validation of a bladder symptom screening tool in women with incontinence due to overactive bladder
L. Cardozo (2014)
10.1016/J.ACURO.2011.06.015
Estudio epidemiológico descriptivo del diagnóstico de hiperactividad del detrusor en las unidades de diagnóstico urodinámico de España
Luis Prieto (2012)
10.1186/s12955-014-0147-7
Development of the Incontinence Utility Index: estimating population-based utilities associated with urinary problems from the Incontinence Quality of Life Questionnaire and Neurogenic Module
J. Cuervo (2014)
10.1007/s11934-010-0126-4
Percutaneous Tibial Nerve Stimulation and Overactive Bladder
Kamran P Sajadi (2010)
10.1016/j.maturitas.2010.03.010
Overactive bladder.
Karen Wallace (2010)
10.1371/journal.pone.0220615
Trends in the use of antimuscarinics and alpha-adrenergic blockers in women with lower urinary tract symptoms in Taiwan: A nationwide, population-based study, 2007-2012
Yu-Hua Lin (2019)
10.1111/bju.13008
The Swiss Continence Foundation Award: promoting the next generation in neuro‐urology and functional urology
U. Mehnert (2015)
10.7591/cornell/9781501702136.001.0001
Weill Cornell Medicine
A. Gotto (2016)
Educating Medical Directors of Employers, Health Plans and Provider Systems FEATURED ARTICLES INCLUDE: Clinical Advances and Therapeutic Strategies for Patients with Epilepsy Exploring the Recent Advances in Biosimilars Novel Agents in the Treatment of Castration-Resistant Prostate Cancer
Ronald D. Hunt (2017)
10.1002/14651858.CD009252
Feedback or biofeedback to augment pelvic floor muscle training for urinary incontinence in women.
R. Herderschee (2011)
10.1007/s00192-017-3417-1
De novo overactive bladder following midurethral sling procedures: a systematic review of the literature and meta-analysis
Vasilios Pergialiotis (2017)
Studies on inhibitory modulation of urinary tract motility
Na Guan (2014)
10.1007/s12603-019-1190-1
Association between Sarcopenia and Overactive Bladder in Elderly Diabetic Patients
Satoshi Ida (2019)
10.5152/tud.2015.94210
Role of percutaneous posterior tibial nerve stimulation either alone or combined with an anticholinergic agent in treating patients with overactive bladder.
Sadık Kızılyel (2015)
10.1016/j.sxmr.2016.04.002
How the Emotional Motor System Controls the Pelvic Organs.
G. Holstege (2016)
10.1007/s40266-015-0301-x
Treatment of Overactive Bladder in the Elderly Female: The Case for Trospium, Oxybutynin, Fesoterodine and Darifenacin
Scott C McFerren (2015)
10.1185/03007995.2010.541433
Tolerability of solifenacin and oxybutynin immediate release in older (>65 years) and younger (≤65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study
S. Herschorn (2011)
10.5213/inj.1624678.339
Antimuscarinic Agent Treatment Affecting Patient-Reported Outcomes in Overactive Bladder Syndrome With Depressive Symptoms
Kyu Shik Kim (2016)
10.1016/j.ucl.2017.04.001
Understanding the Economic Impact of Neurogenic Lower Urinary Tract Dysfunction.
Isaac Palma-Zamora (2017)
10.1186/s12877-017-0690-2
An investigation of factors predicting the type of bladder antimuscarinics initiated in Medicare nursing homes residents
Daniela C. Moga (2017)
10.1016/j.urology.2012.09.028
Defining and managing overactive bladder: disagreement among the experts.
U. Lee (2013)
10.1097/SPV.0b013e31822f816f
Repeat Intradetrusor Injections of Onabotulinum Toxin A for Refractory Idiopathic Overactive Bladder Patients: A Single-Center Experience
A. Gousse (2011)
10.4236/OJOG.2017.78092
Very Low, Real-Time Rate of Urinary Retention after Intradetrusor Botox® for Non-Neurogenic Overactive Bladder
Kirin K. Syed (2017)
10.1371/journal.pone.0217984
Depression is a major risk factor for the development of dementia in people with lower urinary tract symptoms: A nationwide population-based study
Ming-Jung Ou (2019)
10.5489/cuaj.1613
Global perspective of treatment failures.
S. Herschorn (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar